Detalhe da pesquisa
1.
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Rheumatology (Oxford)
; 56(8): 1386-1394, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28460083
2.
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Clin Exp Rheumatol
; 35(3): 390-400, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28079500
3.
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Clin Exp Rheumatol
; 34(1): 32-6, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26575982
4.
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Pediatr Rheumatol Online J
; 15(1): 86, 2017 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29282090
5.
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Arthritis Care Res (Hoboken)
; 67(4): 475-83, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25186034
6.
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
J Rheumatol
; 39(4): 720-7, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22382341
7.
Rinderpest eradication: appropriate technology and social innovations.
Science
; 337(6100): 1309-12, 2012 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22984063
8.
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Arthritis Res Ther
; 14(1): R11, 2012 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22251436